<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649581</url>
  </required_header>
  <id_info>
    <org_study_id>7058</org_study_id>
    <nct_id>NCT03649581</nct_id>
  </id_info>
  <brief_title>Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders</brief_title>
  <acronym>NeuroSplitsz</acronym>
  <official_title>Investigation of Clinical, Cognitive and Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current diagnostic criteria for schizophrenia and other psychotic disorders are
      relatively broad and lack precision. Therefore, distinct diseases may be grouped together
      under the same diagnostic category, although these diseases may differ according to their
      clinical expression, prognosis and perhaps their physiopathological causes.

      We think that identifying subforms of psychotic disorders that are more homogeneous will
      better enable to understand their respective physiopathological causes and find personalized
      treatments.

      This study will compare two subforms of psychotic disorders that have been clinically
      distinguished in the 1970s. These phenotypes have however not been validated yet using
      scientific investigations.

      Using clinical assessments, cognitive evaluations and neurophysiological measures (fMRI)
      investigating the domains of affect and psychomotoricity , we expect that these two subforms
      will differ on their clinical, cognitive and neurophysiological characteristics, namely:
      hebephrenia will be associated with deficits on the affect markers , and respect
      psychomotoricity (catatonia scales, tests assessing movement planification) whereas the
      opposite pattern will be observed for periodic catatonia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">February 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of affect</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Compare two groups of markers relating respectively to affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of psychomotoricity</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Compare two groups of markers relating to psychomotricity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>patient with schizophrenia and periodic catatonia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patient with schizophrenia and hebephrenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compare the two groups of schizophrenic patients</intervention_name>
    <description>Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:
abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),
abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).</description>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>patient with schizophrenia and hebephrenia</arm_group_label>
    <arm_group_label>patient with schizophrenia and periodic catatonia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compare the two groups of schizophrenic patients versus volunteers</intervention_name>
    <description>compare the results of the schizophrenic patient group with healthy volunteers</description>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>patient with schizophrenia and hebephrenia</arm_group_label>
    <arm_group_label>patient with schizophrenia and periodic catatonia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  for both patients and controls

          -  male or female willing to participate and who have signed up the legal document

          -  under the protection of health insurance for patients only

          -  schizophrenia or schizo-affective disorder according to the DSM-5 criteria

          -  periodic catatonia or hebephrenia accordin to WKL classification

          -  clinically stable for at least 2 months

          -  in or out patients for controls only

          -  no psychiatric history

        Exclusion Criteria:

          -  for both patients and controls

          -  current severe or unstable somatic illness

          -  neurological history (epilepsia, brain injury, brain surgery…)

          -  current substance use disorder (DSM-5)

          -  current major depressive disorder (DSM-5)

          -  mental retardation (IQ &lt; 70)

          -  pregnancy, breast feeding

          -  current legal control

          -  contra-indication for fMRI for controls only psychotropic intake during the last 3
             weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabrice BERNA, MD</last_name>
    <phone>03 88 11 64 62</phone>
    <email>fabrice.berna@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice BERNA, MD</last_name>
      <phone>33388116462</phone>
      <email>fabrice.berna@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice BERNA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack FOUCHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie CLAUSS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier MAINBERGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

